ライフサイエンスコーパス: bilirubin

1 ost portal veins, with no elevation of serum bilirubin.

2 r characterized by an inability to conjugate bilirubin.

3 sponsible for the reduction of biliverdin to bilirubin.

4 isomerization, similar to that observed for bilirubin.

5 r, PFOA was associated with decreased direct bilirubin.

6 histology; combination of ALP+histology; and bilirubin.

7 luding UGT1A1, an enzyme known to metabolise bilirubin.

8 tion, mural nodules, serum tumor markers, or bilirubin.

9 fe and efficacious method for reducing total bilirubin.

10 ) then catalyzes conversion of biliverdin to bilirubin.

11 amma-glutamyl transpeptidase (GGT), or total bilirubin.

12 1A1 (UGT1A1) and the inability to metabolize bilirubin.

13 imation per 1-SD increase in log-transformed bilirubin 0.58 [95% CI 0.39-0.84]; P = 0.005), which was

14 861.8 +/- 813.7 U/L; p </= 0.01), and total bilirubin (0.13 +/- 0.05 vs 0.30 +/- 0.14 mg/dL; p </= 0

15 ferase (AST; 26 versus 21, P = 0.01), direct bilirubin (0.13 versus 0.1, P = 0.01), prothrombin time

16 death included higher than 115 mumol/L serum bilirubin 2-5 days after biliary stenting (HR 3.274, P=0

17 o [1.2, P < 0.001; 1.1, P = 0.001] and total bilirubin (2.7, P = 0.001; 2.1, P = 0.05)).

18 mes the upper limit of normal) with a normal bilirubin 28 days after starting MLE4901, which normalis

19 ratio (1.5 and 1.2, respectively) and total bilirubin (4.6 and 2.7) were significantly greater compa

20 and they had elevated median values of total bilirubin (6.67 mg/dL), alanine aminotransferase (2288.8

21 ariation, was strongly associated with total bilirubin (a 0.68-SD increase in bilirubin levels per T

22 Bilirubin, a key biomarker for the jaundice and its clin

23 Circulating bilirubin, a natural antioxidant, is associated with dec

24 Bilirubin, a potent endogenous antioxidant, was found to

25 isk of jaundice, a condition in which excess bilirubin accumulates in blood.

26 parameters like total leucocyte count, urea, bilirubin, alanine transaminase, aspartate transaminase,

27 ose To construct a nomogram with the albumin-bilirubin (ALBI) grade to assess the long-term outcomes

28 The model, the Albumin-Bilirubin (ALBI) grade, performed at least as well as th

29 ansferase (ALT), alkaline phosphatase, total bilirubin, albumin, creatinine, and hemoglobin; prothrom

30 e, tumor capsule, pathological grades, total bilirubin, albumin, prothrombin time, alpha-fetoprotein,

31 kers such as carcinoembryonic antigen (CEA), bilirubin, alpha fetoprotein (AFP), and c-reactive prote

32 count, raised serum ALT, raised serum total bilirubin and a lack of endoscopy were independent predi

33 liver triglyceride content and elevated ALT, bilirubin and alkaline phosphatase due to three hepatic

34 e correlated to the diseases and also plasma bilirubin and alkaline phosphatase.

35 Unconjugated bilirubin and ammonia were or tended to be elevated in F

36 ive bile production and biliary secretion of bilirubin and bicarbonate were significantly higher afte

37 ditionally to improved laboratory variables (bilirubin and creatinine), the short-term mortality (up

38 located at chromosome 2q37.1 for both total bilirubin and direct bilirubin, with 29 SNPs reaching st

39 of tryptophan, caffeine and its metabolites, bilirubin and ergothioneine, and significantly higher le

40 of the inherent specific interaction between bilirubin and HSA.

41 ients, PCLD patients had significantly lower bilirubin and international normalized ratio at waitlist

42 or linear trend in the AUC of serum indirect bilirubin and iron levels).

43 hemeoxygenase activity product biliverdin to bilirubin and is directly activated by insulin receptor

44 CN II exhibit residual capacity to conjugate bilirubin and may present a normal life expectancy.

45 important biomarkers for liver function are bilirubin and prothrombin time expressed as Internationa

46 ositive association was found between direct bilirubin and T2D risk comparing extreme quartiles, simi

47 New albumin, bilirubin, and alkaline phosphatase grade 3/4 toxicities

48 natural biochromophores chlorophyll, hemin, bilirubin, and biliverdin and to high mass fluoroalkyl-f

49 Elevations of serum transaminases, bilirubin, and creatine kinase were infrequent and simil

50 transferase, alanine aminotransferase, total bilirubin, and gamma glutamyl transferase were higher in

51 port of many compounds, such as fatty acids, bilirubin, and heme.

52 l cholesterol (TC), leptin, total and direct bilirubin, and increases in adiponectin and expression o

53 as HDL cholesterol, free fatty acids, FGF21, bilirubin, and lactate depend on the microbiome.

54 umol/L (>/=1 mg/dL), normal conjugated serum bilirubin, and no evidence of hepatitis, cholestasis, or

55 eased plasma alanine aminotransferase, total bilirubin, and serum alkaline phosphatase levels by 86%,

56 ology Score 2, plasma lactate deshydrogenase bilirubin, and serum ferritin.

57 of hepatic cholesterol and serum bile salts, bilirubin, and transaminase levels.

58 Bilin chromophores and bilirubin are involved in relevant biological functions

59 The well-established role of bilirubin as an antioxidant is a potential explanation f

60 lysis identified baseline cholinesterase and bilirubin as the most important variables (forest-averag

61 icators on univariate analysis were albumin, bilirubin, ascites, tumor size 5 cm or smaller, focality

62 sis related HCC patients pre-procedure serum bilirubin, ascites, tumour size and female gender predic

63 parameters (international normalized ratio, bilirubin, aspartate aminotransferase, alanine aminotran

64 an increase in alanine transaminase or total bilirubin between both CSL112 arms and placebo was withi

65 Alterations in the bilirubin/biliverdin ratio and ergothioneine can indicat

66 1 month included operation type, NAS >/= 5, bilirubin, body mass index, hemoglobin A1C, and dyslipid

67 we developed a sensitive genetically encoded bilirubin (BR)-inducible fluorescence sensor (eUnaG) to

68 l day 8 of critical illness increased plasma bilirubin but reduced the occurrence of biliary sludge a

69 and heme degradation products, particularly bilirubin by using our recently created mouse model, whi

70 Median total bilirubin, CA19-9, and carcinoembryonic antigen (CEA) le

71 ole enzyme responsible for the metabolism of bilirubin, can be induced following activation of Nrf2.

72 stress-responsive enzyme converting heme to bilirubin, carbon monoxide, and free iron, which exerts

73 Higher bilirubin, coagulopathy, leukocytosis, and thrombocytope

74 aling significant association between direct bilirubin concentration and type-2 diabetes risk.

75 ue (including grade 3 in three patients) and bilirubin concentration increases (including grade 3-4 i

76 lkylating agent) and last available pre-HSCT bilirubin concentration of greater than or equal to the

77 of erythrocytes in relation to their plasma bilirubin concentration.

78 r) were then utilized to calculate the total bilirubin concentration.

79 type-2 diabetes risk with increasing direct bilirubin concentrations (OR: 0.70, 95% CI: 0.53-0.89, P

80 ic acid can improve alkaline phosphatase and bilirubin concentrations but does not alter the disease

81 conditioning therapy for unconjugated serum bilirubin concentrations of at least 17.1 mumol/L (>/=1

82 's 65% fluid overload, raised creatinine and bilirubin concentrations, and severe acidosis were all m

83 nsferase levels, and two (17%) had increased bilirubin concentrations.

84 Defects in bilirubin conjugation could increase levels of unconjuga

85 Bilirubin correlated inversely to NPP7 and was higher in

86 The primary endpoint was the change of serum bilirubin, creatinine and serum BUN levels before and af

87 lysis, thrombophilia, and inflammation (LDH, bilirubin, D-dimer, C-reactive protein [CRP]) improved.

88 In all patients plasma bilirubin (daily) and liver enzymes (alanine aminotransf

89 aminotransferase (AST), day-1 lactate, day-3 bilirubin, day-3 international normalized ratio (INR), a

90 cholestasis was defined as sustained direct bilirubin (DB) <2 mg/dL, and treatment failure as liver

91 ase (AST), total bilirubin (TBIL) and direct bilirubin (DBIL) with minimal bile duct damage in the AN

92 Serum total bilirubin decreased after PEBD in FIC1 (8.1 +/- 4.0 vs.

93 The mean direct bilirubin decreased from 6.4 +/- 4 mg/dL to 0.2 +/- 0.1

94 he capabilities to not only quantitate total bilirubin (Deming-regression slope of 0.95, R(2) = 0.990

95 genes involved in intestinal maturation and bilirubin detoxification.

96 1, in combination with the overproduction of bilirubin during the developmental stage, acts as a bott

97 4 patients, of which 1 had concomitant total bilirubin elevation.

98 ts in the deferred treatment group had total bilirubin elevations.

99 developmental stage, acts as a bottleneck to bilirubin elimination and predisposes the infant to high

100 ) or rare but severe, increasing the risk of bilirubin encephalopathy (Crigler-Najjar syndrome).

101 al hyperbilirubinemia (SNH) and the onset of bilirubin encephalopathy and kernicterus result in part

102 The term kernicterus, or bilirubin encephalopathy, is used to describe pathologic

103 mentary tools in the diagnostics of neonatal bilirubin encephalopathy.

104 odalities in the evaluation of neonates with bilirubin encephalopathy.

105 PN group, as soon as PN was started on day 8 bilirubin fell and the two groups became comparable.

106 (three [1%] vs 13 [5%]), and increased blood bilirubin (five [2%] vs 14 [5%]).

107 72 hours of age or a decrease in total serum bilirubin for infants older than 72 hours of age who rec

108 signed to measure the concentration of total bilirubin from several drops of blood at the point of ca

109 According to this model, hepatocytic bilirubin glucuronide can follow a liver-to-blood shuttl

110 is of findings with the endogenous compound, bilirubin glucuronide.

111 or less, compared to 36% in those with total bilirubin greater than 1.3 mg/dL.

112 ACLFs) and presence of liver failure (total bilirubin >/=12 mg/dL) at ACLF diagnosis.

113 Age >50 years, liver cirrhosis, bilirubin >1.1 mg/dl (P < 0.01, each), platelets <100,00

114 cations, EAD (defined by postoperative day 7 bilirubin >10 mg/dL or international normalized ratio >1

115 pper limit of normal or an increase in total bilirubin >2 times the upper limit of normal) or a renal

116 ement therapy, and 28% had liver impairment (bilirubin >34 mumol/L), each of these parameters definin

117 n, elevated AST and/or ALT (<300 U/L), serum bilirubin >34 mumol/L, and elevated INR.

118 , variceal bleeding, prothrombin <45%, serum bilirubin >45 mumol/L, albumin <28 g/L, and/or creatinin

119 N rats, indicating recovery from the hepatic bilirubin-handling defect in these animals.

120 Increased serum bilirubin has been shown to be a negative predictive fac

121 Serum bilirubin higher than 115 mumol/L 2-5 days after the pro

122 weight among left lobes, higher preoperative bilirubin, higher portal reperfusion pressure, higher do

123 Unlike bilirubin, however, the phylloxanthobilin Z isomers phot

124 erase (HR 4.22, p 0.016), raised serum total bilirubin (HR 5.79, p 0.008) and lack of an endoscopic p

125 of the nanoclusters was strongly quenched by bilirubin in a concentration dependent manner by virtue

126 tly benign, excessively high levels of serum bilirubin in a small percentage of newborns can cause bi

127 ed with neonatal jaundice and circulation of bilirubin in blood at high concentration due to increase

128 for sensitive and reliable detection of free bilirubin in blood serum samples using human serum album

129 been successfully used for detection of free bilirubin in blood serum samples.

130 inical study using BiliSpec to measure total bilirubin in neonates at risk for jaundice at Queen Eliz

131 was a moderate transient elevation in serum bilirubin in one participant.

132 ted levels of alanine transaminase and total bilirubin in patients receiving TACE plus RT compared wi

133 was exploited for colorimetric detection of bilirubin in serum sample with a DL of 200+/-19 nM by fo

134 nd grade 1 or 2 elevation in levels of total bilirubin (in 12%), alkaline phosphatase (in 21%), and a

135 nvestigating molecular mechanisms underlying bilirubin-induced encephalopathy, and searching for pote

136 Bilirubin-induced neurologic dysfunction (BIND) and kern

137 in a small percentage of newborns can cause bilirubin-induced neurologic dysfunction, potentially le

138 evelopmentally induced hyperbilirubinemia to bilirubin-induced neurological dysfunction (BIND) and CN

139 een developed to make it possible to examine bilirubin-induced neurotoxicity from multiple directions

140 Age, bilirubin, INR, and creatinine (ABIC) score was B or C i

141 cation, MEAF is a continuous score, based on bilirubin, international normalized ratio, and alanine a

142 livers functioned, and serum transaminases, bilirubin, international normalized ratio, and lactate l

143 (Model for End-Stage Liver Disease and age, bilirubin, international normalized ratio, creatinine sc

144 Serum bilirubin is a potent endogenous antioxidant and has bee

145 Owing to the fact that bilirubin is metabolized solely through glucuronidation

146 , caused by the accumulation of unconjugated bilirubin, is one of the most common clinical diagnoses

147 ter; P<0.001 for both comparisons) and total bilirubin level (-0.02 and -0.05 mg per deciliter [-0.3

148 f predicted risk on the continuous variables bilirubin level and cholinesterase level was determined.

149 recipients with metastatic NETs whose total bilirubin level at transplantation was 1.3 mg/dL or less

150 ased significantly with elevated serum total bilirubin level at transplantation.

151 sk factors for adverse outcomes in AC: total bilirubin level greater than 10 mg/dL and white blood ce

152 nt greater than 20000 cells/microL and total bilirubin level greater than 10 mg/dL are independent pr

153 el results provide evidence that an elevated bilirubin level is causally associated with the risk of

154 e, 13.5-18.0 g/dL [8.38-11.17 mmol/L]) and a bilirubin level of 62 micromol/L (normal range, 3-17 mic

155 ercentage of participants with a serum total bilirubin level of less than 1.5 mg/dL with his/her nati

156 io, 3.4; 95% CI, 1.2-9.5; P = .02) and total bilirubin level of more than 10 mg/dL (odds ratio, 5.4;

157 No elevations in the bilirubin level of more than twice the upper limit of th

158 udy a potential causal effect of serum total bilirubin level on T2D risk.

159 on ventilator and dialysis and had a higher bilirubin level than other candidates.

160 ecile, glomerular filtration rate, and total bilirubin level were included in a simplified model and

161 lasma PfHRP2 level, parasitemia level, total bilirubin level, and RCD at a shear stress of 1.7 Pa wer

162 least 15% from baseline, and a normal total bilirubin level.

163 erase, aspartate aminotransferase (AST), and bilirubin levels <1.5 times the upper limit of normal we

164 50 activity (CH50 > 10%; P = .004), elevated bilirubin levels (P < .0001), and the need for transfusi

165 rticipants with 2,532 diabetes cases), serum bilirubin levels (total, direct and indirect) increased

166 Baseline bilirubin levels above 1.5 mg/dL were associated with a

167 serum showed a hepatic effect; e.g. reduced bilirubin levels and albumin/globulin ratio.

168 ssociated with elevated aminotransferase and bilirubin levels and elevated rapid plasma reagin titers

169 ort the protective association between serum bilirubin levels and incident T2D in the middle-aged and

170 l and prospective associations between serum bilirubin levels and T2D risk in the Dongfeng-Tongji (DF

171 Alkaline phosphatase and bilirubin levels correlate with the risk of liver transp

172 Moderate elevations in bilirubin levels have anti-diabetic effects.

173 ytes, and cholangiocytes and elevated direct bilirubin levels in blood sera of GUNN rats, indicating

174 The mean difference between bilirubin levels measured with BiliSpec and the referenc

175 principal component analysis, which included bilirubin levels or clinical icterus, and lactate dehydr

176 with total bilirubin (a 0.68-SD increase in bilirubin levels per T allele; P < 1 x 10(-122)) and was

177 m baseline in alkaline phosphatase and total bilirubin levels that differed significantly from the ch

178 In ATP11C-deficient mice, plasma total bilirubin levels were 6-fold increased, compared to cont

179 dle-aged and elderly adults; instead, direct bilirubin levels were associated with increased risk of

180 sting glucose, triglycerides, uric acid, and bilirubin levels were decreased in the salsalate group c

181 ptin, adiponectin, insulin, total and direct bilirubin levels were measured.

182 Total and indirect bilirubin levels were not significantly associated with

183 Serum bilirubin levels were significantly decreased by 32% dur

184 ictive value for baseline cholinesterase and bilirubin levels with a highly nonlinear influence for e

185 ternational normalized ratio and albumin and bilirubin levels, as well as presence or absence of asci

186 cantly associated with higher creatinine and bilirubin levels, international normalized ratio, and vi

187 Per 1-SD increase in log-transformed bilirubin levels, we observed a 25% (OR 0.75 [95% CI 0.6

188 UDPGT family directly associated with serum bilirubin levels, which is in turn implicated with reduc

189 ulocyte counts compared to patients with low bilirubin levels.

190 GT1A1 in the small intestine to reduce serum bilirubin levels.

191 s done in all the patients with normal serum bilirubin levels.

192 d predisposes the infant to high total serum bilirubin levels.

193 used more elevations in aminotransferase and bilirubin levels.

194 baseline albumin >/=3.5 g/dL, baseline total bilirubin </=1.2 mg/dL, absence of cirrhosis, and hepati

195 0%), and have adequate organ function (serum bilirubin </=3.0 mg/dL and serum creatinine </=3.0 mg/dL

196 re higher albumin (>/=3.5 g/dL), lower total bilirubin (</=1.2 g/dL), absence of cirrhosis, and absen

197 able mortality included female sex, elevated bilirubin, lymphopenia, and mechanical ventilation; grad

198 Elevated conjugated bilirubin magnified the association between parenteral m

199 , gamma-glutamyltransferase (GGT) and direct bilirubin, markers of liver toxicity, were obtained from

200 Serum total bilirubin may serve as a predictor of poor posttransplan

201 s syndrome is a common inherited disorder of bilirubin metabolism, characterised by mild, unconjugate

202 her additional glucose treatments induce the bilirubin-metabolizing enzyme--UDP-glucuronosyltransfera

203 Creatinine, total bilirubin, minority ethnicity, graft under-sizing, life

204 e greater than three times the ULN and total bilirubin more than twice the ULN) after treatment of th

205 he prognosticators of overall survival to be bilirubin, no ascites, tumor size 5 cm or smaller, solit

206 ated with poor prognosis were baseline serum bilirubin, no reversibility of type-1 HRS, lack of resol

207 of type-1 HRS were age, high baseline serum bilirubin, nosocomial infection, and reduction in serum

208 gamma-glutamyltransferase, without increased bilirubin, occurred in 11 (39%) of 28 patients who recei

209 glutamyl transpeptidase of 117.9%, P<0.0001; bilirubin of 50.0%, P<0.001; alanine aminotransferase of

210 defined as a rate of increase in total serum bilirubin of less than 0.2 mg per deciliter per hour for

211 nt duration, age, baseline serum creatinine, bilirubin or albumin, baseline mean arterial pressure, o

212 n of association with either elevated direct bilirubin or GGT; however, PFOA was associated with decr

213 mic time, peak aspartate transaminase, day 5 bilirubin or international normalized ratio after transp

214 DIO mice were treated with bilirubin or vehicle for 14 days.

215 rade >/= 3b) after stage 1 (OR = 3.4), serum bilirubin (OR = 4.4), serum creatinine (OR = 5.4), and c

216 lity but not serum alanine aminotransferase, bilirubin, or amylase.

217 rmalities in alanine aminotransferase, total bilirubin, or hemoglobin were observed.

218 When integrated with bilirubin oxidase (BOD) and single walled carbon nanotub

219 quinone glucose dehydrogenase (PQQ-GDH) and bilirubin oxidase (BOD) at anode and cathode, respective

220 Previously we showed that an effective bilirubin oxidase (BOD)-based biocathode using graphene

221 H) based bioanode and Myrothecium verrucaria bilirubin oxidase (BOx) based biocathode was constructed

222 e by the use of high potential cathodes like bilirubin oxidase (BOx) or iron-aminoantipyrine (Fe-AAPy

223 te oxidase (hSOx) and Myrothecium verrucaria bilirubin oxidase (MvBOx) and nanostructured gold electr

224 s mediator, while the cathode catalysts were bilirubin oxidase and [Os(2,2'-bipyridine)2(poly-vinylim

225 ical pre-treatment with a silane derivative, bilirubin oxidase from Myrothecium verrucaria was immobi

226 ehydrogenase from Corynascus thermophiles or bilirubin oxidase from Myrothecium verrucaria, were perf

227 d in biocathode using immobilized laccase or bilirubin oxidase in order to generate sufficient power.

228 notubes, was coupled with an oxygen-reducing bilirubin oxidase on gold nanoparticle dispersed on gold

229 enemethyl anthracene-2-carboxylate, and then bilirubin oxidase was immobilized within a polymer.

230 Glucose oxidase and bilirubin oxidase were selected as anodic and cathodic e

231 system has a biocathode made from laccase or bilirubin oxidase, and the anode is made from a zinc pla

232 Glucose dehydrogenase-based anode and bilirubin oxidase-based cathode were assembled to a quas

233 nm) and the mono- and trinuclear Cu sites of bilirubin oxidases.

234 nal hazards analysis was conducted and total bilirubin (P < 0.001, hazard ratio [HR] = 2.09, 95% conf

235 nsulin, blood urea nitrogen, creatinine, and bilirubin (P < 0.05).

236 .007), alanine aminotransferase (P = 0.027), bilirubin (P = 0.005), and low platelet counts (P > 0.00

237 ites (p = 0.030, OR = 1.212), elevated serum bilirubin (p = 0.007, OR = 4.357) and large tumour size

238 m (p = 0.049, OR = 2.410) and elevated serum bilirubin (p = 0.036, OR = 1.517) predicted AHD.

239 On univariate analysis elevated serum bilirubin (p = 0.046) and low serum albumin (p = 0.035)

240 aminotransferase (ALT; p<0.0001), conjugated bilirubin (p=0.0006), and gamma-glutamyltranspeptidase (

241 , respectively), as well as higher levels of bilirubin (P=0.004) and C-reactive protein (P=0.006).

242 dth on computed tomography and at operation, bilirubin, pancreatojejunostomy technique, underlying pa

243 T include: graft type and size, preoperative bilirubin, portal reperfusion pressure, donor age, and d

244 R0 negative margin rate, postoperative peak bilirubin, postoperative intensive care unit admission r

245 h catalyzes the degradation of heme into the bilirubin precursor biliverdin, ferrous iron, and CO dur

246 Tumours larger 5 cm with elevated bilirubin predicted AHD post-TACE.

247 idic level for the ultimate purpose of total bilirubin quantitation.

248 n in controls and were related to conjugated bilirubin (r = 0.799-0.541, P < 0.05).

249 These results indicate that bilirubin regulates cholesterol metabolism, adipokines a

250 al volunteers spiked with varying amounts of bilirubin; results measured using BiliSpec correlated we

251 evident from a significant decrease in serum bilirubin, reticulocyte counts, and serum erythropoietin

252 ncrease levels of unconjugated or conjugated bilirubin (Rotor syndrome).

253 n at 12 facilities that used universal serum bilirubin screening before (January 1, 2010, through Apr

254 d experimental conditions, the probe detects bilirubin selectively in the presence of other interferi

255 nor after brain death or circulatory death), bilirubin, smoking history, and whether the liver was sp

256 phalopathy, is used to describe pathological bilirubin staining of the basal ganglia, brain stem, and

257 Bilirubin stimulated suicidal death of human erythrocyte

258 Total bilirubin (T-Bil) is an important clinical diagnostic ma

259 ase (ALT), alkaline phosphatase (AST), total bilirubin (TBIL) and direct bilirubin (DBIL) with minima

260 ) was decreased to normal level, while total bilirubin (TBIL) and liver function were significantly i

261 of alanine aminotransferase (ALT) and total bilirubin (TBL).

262 Recalibration of bilirubin testing instruments.

263 liver inflammation and mean serum levels of bilirubin than mice receiving control antibodies (191 mu

264 the impaired ability of UGT1A1 to eliminate bilirubin that contributes to hyperbilirubinemia-induced

265 rth that lead to the rapid increase in serum bilirubin, the events that control delayed expression of

266 gation could increase levels of unconjugated bilirubin; the effects can be benign and frequent (Gilbe

267 of alanine or aspartate aminotransferases or bilirubin; there were no deaths or discontinuations resu

268 The probe detects the bilirubin through FRET mechanism.

269 es, glucose, creatinine, uric acid, albumin, bilirubin, total cholesterol, triglycerides, high-densit

270 e albumin and platelet count, as well as the bilirubin, transaminases, and alkaline phosphatase, afte

271 : at two months after treatment termination, bilirubin-treated DIO mice remained insulin sensitive wi

272 Compared to controls, bilirubin-treated mice exhibited reductions in body weig

273 The improved metabolic control achieved by bilirubin-treated mice was persistent: at two months aft

274 aimed at determining the mechanisms by which bilirubin treatment reduces obesity and insulin resistan

275 Mechanistically, bilirubin triggered rapid Ca(2+) influx, sphingomyelinas

276 Bilirubin triggers suicidal erythrocyte death, thus cont

277 ignificant reduction of serum transaminases, bilirubin, triphosphate nick-end labeling staining, casp

278 , which exhibit severe levels of total serum bilirubin (TSB) because of a developmental delay in expr

279 n exposed to excessive levels of total serum bilirubin (TSB) during the neonatal period.

280 is recommended for newborns with total serum bilirubin (TSB) levels thought to place them at risk for

281 undice are based on age-specific total serum bilirubin (TSB) levels.

282 risk from baseline values of cholinesterase, bilirubin, type of primary tumor, age at radioembolizati

283 directly reflecting in elevated unconjugated bilirubin (UCB; main phenotypic feature of GS) and iron,

284 ade of 3 or more based on clinical symptoms, bilirubin, ulcer, pancreatitis, ascites, or radioemboliz

285 nce, it was applied for the determination of bilirubin using both colorimetric and fluorimetric techn

286 97 (R(2) = 0.960) when compared to the total bilirubin values determined in the clinical laboratory.

287 nalyses, rs6742078, which explained 19.5% of bilirubin variation, was strongly associated with total

288 n the Norfolk Island cohort increased direct bilirubin was associated with a 28% reduction in type-2

289 55x10(6) L mole(-1) between the HSA-AuNC and bilirubin was discerned.

290 il the end of the 7-day intervention window, bilirubin was higher in the late PN than in the early PN

291 Bilirubin was inversely associated with the renal end po

292 e fluorescence response of HSA-AuNCs against bilirubin was practically unaltered over a wide pH (6-9)

293 ative association between CVD-risk and serum bilirubin we further explored potential associations usi

294 n levels of prothrombin time, INR, and total bilirubin were, respectively, 33% (Q1-Q3, 21-41), 2.74 (

295 phosphatase, aspartate aminotransferase, and bilirubin, were significantly higher in GF mdr2(-/-) (P

296 o a Low Molecular Weight (LMW) ACE effector, bilirubin, which act in concert to regulate ACE conforma

297 , gamma-glutamyltransferase (GGT), and total bilirubin, which-in combination-attenuated the regressio

298 utilized for interference free detection of bilirubin with minimum detection limit (DL) of 248+/-12

299 icates an independent inverse association of bilirubin with progression of nephropathy in RENAAL and

300 e 2q37.1 for both total bilirubin and direct bilirubin, with 29 SNPs reaching statistical significanc